BCM
TRIB

BBT Capital Management’s Trinity Biotech TRIB Stock Holding History

BBT Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-14,760
Closed -$1.61M – 317
2013
Q3 		$1.61M Sell
14,760
-15,240
-51% -$1.49M 0.08% 208
2013
Q2 		$2.53M Buy
+30,000
New +$2.49M 0.13% 174

Other funds holding TRIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
AAM
ACK Asset Management Greenwich, Connecticut $801M AUM 60.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return

BBT Capital Management's TRIB Position: Q4 2013 in Review

BBT Capital Management sold out of Trinity Biotech (TRIB) in Q4 2013, closing a stake of 14,760 shares — an estimated $1.61M sold.

BBT Capital Management first reported a position in TRIB in Q2 2013 and held it in 2 quarters. The position peaked at $2.53M in Q2 2013. 75 funds tracked by Wall St. Rank hold TRIB as of Q4 2013.

  • BBT Capital Management reported no remaining Trinity Biotech position as of Q4 2013 after selling out during the quarter.
  • BBT Capital Management sold 14,760 Trinity Biotech shares in Q4 2013, an estimated $1.61M.
  • BBT Capital Management first reported a position in Trinity Biotech in Q2 2013 and held it in 2 quarters.
  • BBT Capital Management's Trinity Biotech position peaked at $2.53M in Q2 2013.
  • 75 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2013.

Based on BBT Capital Management's 13F filing for Q4 2013, filed 6 Feb 2014.